Astellas Collaborates with Poseida Therapeutics to Develop New Allogeneic Cell Therapies in Oncology
Shots:
- Astellas reported that its subsidiary, Xyphos Biosciences, & Poseida have signed a research collaboration & license agreement for developing new convertible CAR products using each company’s expertise
- Under the collaboration, Poseida’s allogeneic CAR-T platform & Xyphos’ ACCEL technology will be merged to create a single CAR-T construct for 2 convertible CAR product candidates addressing solid tumors
- Poseida will obtain $50M upfront, a total of $550M incl. development & sales milestones plus contingency payments along with low double-digit tiered royalties as a percentage of net sales. Furthermore, Xyphos will cover Poseida's research costs & handle future product development & commercialization
Ref: Astellas | Image: Astellas
Related News:- Astellas and Pfizer Report the NMPA’s Acceptance of sBLA for Enfortumab Vedotin Plus Keytruda for Treating 1L Bladder Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
